KSM-66® Ashwagandha lowered serum cortisol 27.9% in a double-blind RCT (n=64, Chandrasekhar 2012). The dose that did it was 600 mg per day. Many ashwagandha products on shelf carry 300 mg of an unnamed root extract — half the trial dose, a different extract, no licensor. Same word on the label. A different molecule in the body.
The dose is the single number that decides whether a supplement does anything. Not the hero ingredient on the front panel. Not the count of botanicals. The dose — measured against the published human trial that earned the claim in the first place.
The under-dose is the default, not the exception
Actives cost money. Branded, clinically-studied actives cost more. The cheapest way to put a recognizable name on a label is to add a trace of it — enough to declare, not enough to do. The label still reads "Ashwagandha." The capsule still passes a fingerprint test. The buyer never sees the gap between 300 mg and the 600 mg the study ran on.
This is why trial-matched dosing matters. A claim is only as good as the dose it was measured at. Drop below that dose and you are no longer selling the study — you are selling the name of the study, which is a different product.
Trial-matched dosing, defined
Trial-matched dosing means the active in the capsule is delivered at the dose, form, and standardization used in the human trial that supports the claim — not a rounded-down fraction chosen to hit a price.
It is three numbers held together: the named branded active, the dose from the published study, and the standardization (the % marker the study specified). Change any one and the receipt no longer applies. KSM-66® at 600 mg is not interchangeable with a generic root powder at 600 mg. The trial ran on KSM-66®, standardized to its withanolide spec. That is the thing with the receipt.
Worked examples — the dose that earned each claim
BioPerine®: the 2000% increase in curcumin bioavailability (Shoba & Majeed, Planta Medica 1998) was measured with a specific piperine dose alongside curcumin. Add a pinch below that and you have black pepper extract on the label, not the absorption effect.
Meriva®: 29x higher curcuminoid absorption versus standard curcumin (Cuomo 2011) holds because Meriva® is a phytosome — curcumin bound to phospholipid. Swap in plain curcumin powder and the 29x is gone; the form was the mechanism. Ferrochel®: 4.7x higher iron absorption versus ferrous sulfate (AJCN 2000) is a property of the bisglycinate chelate at its studied dose, not of "iron" generically.
Dose and duration travel together
K2VITAL® MK-7 reduced arterial stiffness 4.1% — in a 3-year double-blind RCT (n=244, Knapen 2015). The number is inseparable from the duration. A product dosed correctly but consumed for three weeks has not reproduced that trial; it has started it. Honest formulation states the dose and the time-course the evidence was built on.
Bacillus coagulans Unique IS-2®: 84.9% of subjects achieved ≥50% less abdominal pain versus 12.7% on placebo (DB-RCT n=108, Madempudi 2019) — at a defined CFU count. With live strains, the dose is the guaranteed CFU through end of shelf life, not at the moment of blending. Under-spec the overage and the count that matters — the one in the consumer's hand at month 18 — falls below the studied dose.
What trial-matched costs — said plainly
It is more expensive. Dosing LGG® to the level behind the 51% lower antibiotic-associated diarrhoea risk (meta-analysis, 12 RCTs), or HIMABERB® Berberine to the 33% HOMA-IR insulin-sensitivity improvement (12-wk RCT), costs more per capsule than a fractional sprinkle. Larger fills mean bigger capsules or two-a-day formats — harder to merchandise than a single small pill.
We name that tradeoff because it is the proof of sincerity. A formulation that costs more to make the dose honest is the one that can carry the study without a footnote shrinking it. "Proprietary blend" exists to hide exactly this — it lets a label list an active without disclosing whether it cleared the trial dose. We will not formulate one.
How to verify a dose before you sign
Three checks before a private-label spec leaves the table. One: is the active the branded, licensor-backed grade the study used — KSM-66®, Curcumin C3 Complex®, BioPerine® — with ® intact and a licensor certificate on file? Two: does the per-serving dose meet or match the published human trial, at the standardization the trial specified? Three: does the COA confirm that dose in the finished batch, with CFU or marker overage carried to end of shelf life?
Insignis Bioscience is the contract-manufacturing arm of Nuvea Essentials, building private label for brands, startups, and clinics across 8 markets — India, UAE, Saudi Arabia, USA, Sri Lanka, Singapore, Nepal, and Myanmar. We formulate to the trial dose and put the receipt — study, n=, %, duration, COA, licensor — next to the claim. Every claim, proven.
Key takeaways
- A claim is only valid at the dose the trial measured — KSM-66® cut cortisol 27.9% at 600 mg/day, not at a 300 mg fraction.
- Form and standardization are part of the dose: Meriva®'s 29x absorption is the phytosome; plain curcumin at the same mg does not reproduce it.
- Dose travels with duration and shelf-life CFU — K2VITAL®'s 4.1% needed 3 years; live strains must hold the studied count to end of shelf life.
- Verify three things before signing: branded licensor-backed grade, per-serving dose matched to the published trial, and a COA confirming it in the finished batch.
Clinical figures cited refer to published human studies on the specific branded active named, at the dose studied — not to any finished product, and not as a claim to diagnose, treat, cure, or prevent any disease. Trademarks are the property of their owners.